Articles On Hera Med (ASX:HMD)

Imugene takes the road to China with a new cell-therapy collab Heramed strikes its second US deal within two days Beverage play Althea says things go better with THC   From China to Canada to the US, ASX life science plays are striking o...

ASX plummets 1.59% or 136.2 points Materials hit hardest, with gold and lithium stocks in retreat Defensive sectors in favour; healthcare and staples crawl into green   Nvidia rally turns into dead cat bounce Things were looking almost ro...

Highlights All 11 sectors on the ASX closed in positive territory Strong movement in retail, banking, and gold stocks Defence and healthcare firms also made key announcements The Australian share market rallied strongl...

ASX surges 1.23pc on broad strength 11 of 11 sectors positive throughout trade ASX just 0.07pc off all-time high Market powers higher with all cylinders firing The ASX moved to its own tune today, making strong gains in the first hour an...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

Imugene and Chimeric have unveiled further promising results for their Car-T immune-oncology assets Rhythm Biosciences shares soar 18% on kit validation results While investors are picky, equity dollars continue to flow   There’s a long d...

Copper prices crash 20pc Materials sector undercuts market, down 2.57pc Info tech rally not enough to push ASX into positive territory   Tech rally fails to lift resources The ASX staged a steady recovery through the day to finish down ju...

 Plenty of biotechs are lodging late in the piece, but without too many ‘dog ate my homework’ excuses Telehealth group looks to post-pandemic recovery   Botanix, Amplia and Vitrafy pass muster with the brokers   Some students hand in thei...

EchoSolv enters Mayo’s gauntlet for FDA nod Echo’s AI flags heart failure before it hits the fan Other ASX stocks that have trialled with Mayo   On July 1, Echo IQ released an announcement that made cardiologists sit a little straighter....

Nanocap health software company HeraMED (ASX:HMD) has been slammed on Monday as the company revealed its US based health clinic partner will no longer use HeraMED’s ‘HeraCARE’ software package. The company blamed changes in the American...

Anatara has taken a different tack post-trial results, while Chimeric is raising funds and Imugene proposes a share consolidation Heramed falls victim to US healthcare funding cuts D-Day looms for Mayne Pharma holders – or will there be a...

ASX posts 0.22pc gains, recovering from dip earlier in the day Xero brings big profit and revenue gains in quarterly report, lifting stock 4.7pc Insurance Australia surges 5.7pc on Royal Automobile Club of Western Australia deal   It was...

Amplia says it has reached the requisite level of ‘partial responders’ in its mid-stage pancreatic cancer study Immutep reports “remarkable” response rates in a German-based lung cancer trial Paradigm wins US ethics approval for knee osteo...

Polynovo and Avita Medical are victims of skittish market behaviour Cyclopharm breathes easier after a good start with US sales Control Bionics raises $2 million to rev up commercialisation   Investor reaction to PolyNovo’s (ASX:PNV) half...

HeraMED inks a partnership with Metronomic to develop postpartum care solution in US Collaboration will integrate Metronomic’s care management solution with HeraMED’s solution Integrated solution capitalising on growing demand for improve...

HeraMED accepts $1.02m private placement from three leading institutional investors Latest investment follows a $3.1m two-trance private placement announced in October First investment comes from a leading impact fund   Special Report: H...

Highlights  Prospech reports assay results with stock up by over 14%. Hera Med secures investment, shares rise nearly 10%. LCL Resources completes trenching, shares gain over 11%. In recent trading, shares of Prospech, Hera Med,...

  Prospech (ASX:PRS) has announced further assay results from the ongoing program of sampling and assaying of the historic drill core from holes completed in the 1950s, 60s and early 70s. A total of 307 samples from 25 holes are reported. S...

World Health Organsiation projects a shortfall of 10 million health workers by 2030 HeraMED’s platform helps healthcare providers manage maternity patients remotely Optiscan platform could address shortage of pathologists in Australia and...

CSL expects to be able to taper back on capital spending – at least for the time being Heramed reports record active users for its pregnancy-monitoring platform As with Russell Crowe, we’ll steal Truscreen’s latest achievement from the Kiw...

ASX edges slightly up by 0.12pc as traders rethink rate cuts Consumer staples shine while gold miners gain amid global tensions 29Metals plunges after cash reserve drop and production decline   The ASX ticked up higher by 0.1% on Wednesd...

ASX closes higher led by strong mining sector Wisetech and Mineral Resources suffer heavy losses amid scandals Gold prices soar past $US$2,700 on geopolitical tensions   The ASX rose on Monday after a solid run on Wall Street and some st...

HeraMED has recorded more than 3800 accumulated mothers onto its HeraCARE platform More than 710 pregnant mothers are currently having their pregnancy managed through HeraCARE Recent growth attributed to US-based Broward Health, adding 20...

HeraMED Limited (ASX:HMD), has announced the “soft launch” of HeraCARE within the Telstra Health ecosystem through targeted GP clinics. In November 2023, HeraMED announced its partnership with Telstra Health’s MedicalDirector platform se...

ASX closes lower, but Energy sector blinks green Uranium mining stocks surged on Peter Dutton’s nuclear plans VanEck to launch Australia’s first Bitcoin ETF tomorrow    Local shares closed Wednesday -0.1% lower as gains in Energy were of...

Digital maternity care specialist HeraMED (ASX: HMD) continues to attract strong support for its unique HeraCARE platform. The end-to-end digital maternity monitoring and management platform has reached a record number of accumulated users,...

19 Jun 2024 - A snapshot of the stocks on the move, featuring HeraMED (ASX:HMD), Chariot Corporation (ASX:CC9) and QX Resources (ASX:QXR).

  To register for Friday's webinar click here. HeraMED (ASX:HMD) has reached a record number of accumulated mums on its innovative HeraCARE platform. As at 15 June 2024, the number of accumulated mums on the HeraCARE platform reached 3,533...

Aussie stocks start the week flat; energy and tech sectors lead declines Investor caution prevails ahead of RBA rates decision Chinese Premier Li Qiang meets PM in Canberra today   Aussie stocks had a lacklustre start to the week on Monda...

Aussie shares slipped over 1pc after the King’s Birthday long weekend Mining and Real Estate sectors were the biggest losers among all 11 sectors Chinese EV stocks fell ahead of expected EU tariff hikes   Aussie shares slipped after the K...

Aussie shares rally Rate sensitive stocks gain, led by Tech FTL soars on Newfoundland deal   Aussie shares climbed strongly on Thursday closing above 7,820 as major global central banks began to cut interest rates and in the US, the S&amp...

The ASX200 is trading up just over half a per cent. Most sectors are in the green, Healthcare is leading intraday gains, up around 1.3 per cent, Materials follows, up more than a per cent. The IT sector has dipped the most, down aroun...

Stockhead’s Top 10 at 10, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta...

HeraMED (ASX:HMD) shares are surging following the announcement of a partnership agreement with Telstra Health The collaboration aims to integrate HeraCARE into MedicalDirector Clinical by Telstra Health Telstra Health currently lacks...

PainChek’s European patent HeraMed signs deal with Telstra AdAlta announced interim Phase 1 results Avita lowers 2023 guidance PainChek’s European patent application accepted PainChek (ASX: PCK) announced that the European Patent Office...

The Week That Was The world looks very different this week after the addition of what Barclays economic team calls ‘a complex cocktail of geopolitical risk, mixed macro data, a nervous oil market,’ and a US Fed finding nice things to say ab...

HeraMED (HMD) taps both sophisticated and professional investors for $2.58 million through a private placement The placement involves the issuance of 36.86 million new shares at seven cents per apiece, a 6.67 per cent discount to the com...

ASX dips 0.56% despite a solid kickstart first thing this morning InfoTech outperforms the market again, leading on +0.21% for the day Heavy Minerals banks a 90% bump on some big time garnet news   For 10 fantastic minutes this morning, l...

After a more promising start, the ASX closed out the day up by 0.25%. InfoTech did well (+0.96%), but Health stocks are still anything but, down another 1.97%. Greentech went soaring, up 223% after rock chip assays showed signs of lithium...

HeraMED’s partner E-Lōvu Health signs first three-year deal CareTeq has also signed a deal with the  National Seniors Australia    Medtech company HeraMED (ASX:HMD) says its strategic partner E-Lōvu Health has signed its first three-year...

S&P/ASX 200 closes up 1% – its best performance in about a week  All sectors bar IT and Utilities had green days, with Discretionary and Utilities outperforming Resources & Energy Group had a +183% stonker of a day on its you-beaut...

Paradigm Bio says drug is effective in osteoarthritic dogs HeraMED signed a deal with Fond, a US-based global SaaS platform The first patient has been dosed in Imugene’s clinical trial   Late stage biotech Paradigm Biopharmaceuticals (ASX...

Heramed surged 10pc after signing up a leading private obstetrics  Ecofibre has received two patent grant notifications in the US   Medical data company focusing on maternity care, HeraMED (ASX:HMD), surged as high as 10% this morning aft...

HeraMED (HMD) signs a new contract with Joondalup Obstetrics and Gynaecology Group (JOGG) in Western Australia to deploy its HeraCARE platform The new contract includes an initial purchase of 120 HeraCARE licences and HeraBEAT devices fo...

HeraMED (HMD) announces Gold Coast Hospital will trial its ‘HeraCARE’ platform as its new standard of care for Women Newborn and Children Services (WNCS) The trial will include up to 90 pregnancies for between six to nine months, assessi...

Medical data and technology company HeraMED (ASX:HMD) has announced that it has signed a memorandum of understanding with the Gold Coast Hospital to trial its HeraCARE platform as a new standard of care for their Women Newborn and C...

HeraMED’s first commercial rollout in the US is progressing well Recce Pharma is set to commence Phase I/II clinical trial   Maternity care medtech company, HeraMED (ASX:HMD), says the first phase of its commercial rollout in the US is pr...

HeraMED (HMD) appoints former Nanosonics (NAN) Senior VP, North America, Keith Koby as its President, North America Mr Koby has more than 30 years of experience within the medical technology and devices market He helped Nanosonics’ te...

Race Oncology received positive feedback from the US FDA HeraMed launches HeraCARE in Victoria Mesoblast announced top line results from Phase 3 trial   US FDA pleased with Race Oncology submission Race Oncology (ASX:RAC) has received pos...

HeraMED (HMD) completes a $4 million private placement to fund early commercialisation initiatives The money was raised via the issue of around 30.77 million new ordinary shares priced at 13 cents each – a 13.3 per cent discount to its las...